RÉSUMÉ
According to classical immunology theory, immunoglobulin (Ig) is exclusively produced by differentiated B lymphocytes, which exhibit a typical tetrapeptide chain structure and are predominantly present on the surface of B cells and in bodily fluids. B-Ig is one of the critical effector molecules for humoral immune responses specifically recognising antigens and eliminating them. However, mounting evidence has demonstrated that Ig is widely expressed in non B lineage cells, especially malignant ones (referred to as non B-Ig). Interestingly, non B-Ig mainly resides in the cytoplasm and secretion, but to some extent on the cell surface. Furthermore non B-Ig not only displays a tetrapeptide chain structure but also shows free heavy chains and free light chains (FLCs). Additionally, Ig derived from non B cancer cell typically displays unique glycosylation modifications. Functionally, non B-Ig demonstrated diversity and versatility, showing antibody activity and cellular biological activity, such as promoting cell proliferation and survival, and it is implicated in cancer progression and some immune-related diseases, such as renal diseases.
Sujet(s)
Lymphocytes B , Humains , Animaux , Glycosylation , Lymphocytes B/immunologie , Immunoglobulines/immunologie , Immunoglobulines/métabolisme , Immunoglobulines/composition chimique , Tumeurs/immunologie , Tumeurs/anatomopathologie , Chaines légères des immunoglobulines/composition chimique , Chaines légères des immunoglobulines/immunologie , Chaines légères des immunoglobulines/métabolismeRÉSUMÉ
In contrast to natural antibodies that rely mainly on the heavy chain to establish contacts with their cognate antigen, we have developed a bispecific antibody format in which the light chain (LC) drives antigen binding and specificity. To better understand epitope-paratope interactions in this context, we determined the X-ray crystallographic structures of an antigen binding fragment (Fab) in complex with human CD47 and another Fab in complex with human PD-L1. These Fabs contain a κ-LC and a λ-LC, respectively, which are paired with an identical heavy chain (HC). The structural analysis of these complexes revealed the dominant contribution of the LCs to antigen binding, but also that the common HC provides some contacts in both CD47 and PD-L1 Fab complexes. The anti-CD47 Fab was affinity optimized by diversifying complementary-determining regions of the LC followed by phage display selections. Using homology modeling, the contributions of the amino acid modification to the affinity increase were analyzed. Our results demonstrate that, despite a less prominent role in natural antibodies, the LC can mediate high affinity binding to different antigens and neutralize their biological function. Importantly, Fabs containing a common variable heavy (VH) domain enable the generation of bispecific antibodies retaining a truly native structure, maximizing their therapeutic potential.
Sujet(s)
Anticorps bispécifiques , Antigène CD274 , Antigènes CD47 , Fragments Fab d'immunoglobuline , Anticorps bispécifiques/composition chimique , Anticorps bispécifiques/immunologie , Humains , Antigènes CD47/immunologie , Antigènes CD47/composition chimique , Fragments Fab d'immunoglobuline/composition chimique , Fragments Fab d'immunoglobuline/immunologie , Antigène CD274/immunologie , Antigène CD274/composition chimique , Antigène CD274/antagonistes et inhibiteurs , Cristallographie aux rayons X , Chaines légères des immunoglobulines/composition chimique , Chaines légères des immunoglobulines/immunologie , Modèles moléculairesRÉSUMÉ
Catalytic antibodies possess a dual function that enables both antigen recognition and degradation. However, their time-consuming preparation is a significant drawback. This study developed a new method for quickly converting mice monoclonal antibodies into catalytic antibodies using site-directed mutagenesis. Three mice type monoclonal antibodies targeting hemagglutinin molecule of influenza A virus could be transformed into the catalytic antibodies by deleting Pro95 in CDR-3 of the light chain. No catalytic activity was observed for monoclonal antibodies and light chains. In contrast, the Pro95-deleted light chains exhibited a catalytic activity to cleave the antigenic peptide including the portion of conserved region of hemagglutinin molecule. The affinity of the Pro95-deleted light chains to the antigen increased approximately 100-fold compared to the wild-type light chains. In the mutants, three residues (Asp1, Ser92, and His93) come closer to the appropriate position to create the catalytic site and contributing to the enhancement of both catalytic function and immunoreactivity. Notably, the Pro95-deleted catalytic light chains could suppress influenza virus infection in vitro assay, whereas the parent antibody and the light chain did not. This strategy offers a rapid and efficient way to create catalytic antibodies from existing antibodies, accelerating the development for various applications in diagnostic and therapeutic applications.
Sujet(s)
Anticorps catalytiques , Anticorps monoclonaux , Animaux , Souris , Anticorps monoclonaux/immunologie , Anticorps catalytiques/métabolisme , Anticorps catalytiques/immunologie , Anticorps catalytiques/génétique , Glycoprotéine hémagglutinine du virus influenza/immunologie , Glycoprotéine hémagglutinine du virus influenza/génétique , Mutagenèse dirigée , Virus de la grippe A/immunologie , Domaine catalytique , Humains , Chaines légères des immunoglobulines/génétique , Chaines légères des immunoglobulines/immunologie , Chaines légères des immunoglobulines/métabolisme , Anticorps antiviraux/immunologie , Souris de lignée BALB CRÉSUMÉ
MOTIVATION: Antibody therapeutic candidates must exhibit not only tight binding to their target but also good developability properties, especially low risk of immunogenicity. RESULTS: In this work, we fit a simple generative model, SAM, to sixty million human heavy and seventy million human light chains. We show that the probability of a sequence calculated by the model distinguishes human sequences from other species with the same or better accuracy on a variety of benchmark datasets containing >400 million sequences than any other model in the literature, outperforming large language models (LLMs) by large margins. SAM can humanize sequences, generate new sequences, and score sequences for humanness. It is both fast and fully interpretable. Our results highlight the importance of using simple models as baselines for protein engineering tasks. We additionally introduce a new tool for numbering antibody sequences which is orders of magnitude faster than existing tools in the literature. AVAILABILITY AND IMPLEMENTATION: All tools developed in this study are available at https://github.com/Wang-lab-UCSD/AntPack.
Sujet(s)
Anticorps , Humains , Anticorps/composition chimique , Logiciel , Analyse de séquence de protéine/méthodes , Biologie informatique/méthodes , Chaines lourdes des immunoglobulines/composition chimique , Chaines lourdes des immunoglobulines/immunologie , Chaines légères des immunoglobulines/composition chimique , Chaines légères des immunoglobulines/immunologie , AlgorithmesRÉSUMÉ
H chain-only Igs are naturally produced in camelids and sharks. Because these Abs lack the L chain, the Ag-binding domain is half the size of a traditional Ab, allowing this type of Ig to bind to targets in novel ways. Consequently, the H chain-only single-domain Ab (sdAb) structure has the potential to increase the repertoire and functional range of an active humoral immune system. The majority of vertebrates use the standard heterodimeric (both H and L chains) structure and do not produce sdAb format Igs. To investigate if other animals are able to support sdAb development and function, transgenic chickens (Gallus gallus) were designed to produce H chain-only Abs by omitting the L chain V region and maintaining only the LC region to serve as a chaperone for Ab secretion from the cell. These birds produced 30-50% normal B cell populations within PBMCs and readily expressed chicken sequence sdAbs. Interestingly, the H chains contained a spontaneous CH1 deletion. Although no isotype switching to IgY or IgA occurred, the IgM repertoire was diverse, and immunization with a variety of protein immunogens rapidly produced high and specific serum titers. mAbs of high affinity were efficiently recovered by single B cell screening. In in vitro functional assays, the sdAbs produced by birds immunized against SARS-CoV-2 were also able to strongly neutralize and prevent viral replication. These data suggest that the truncated L chain design successfully supported sdAb development and expression in chickens.
Sujet(s)
Animal génétiquement modifié , Poulets , Chaines lourdes des immunoglobulines , Anticorps à domaine unique , Animaux , Poulets/immunologie , Anticorps à domaine unique/immunologie , Anticorps à domaine unique/génétique , Chaines lourdes des immunoglobulines/génétique , Chaines lourdes des immunoglobulines/immunologie , SARS-CoV-2/immunologie , SARS-CoV-2/génétique , COVID-19/immunologie , Transgènes/génétique , Lymphocytes B/immunologie , Anticorps antiviraux/immunologie , Chaines légères des immunoglobulines/génétique , Chaines légères des immunoglobulines/immunologie , HumainsRÉSUMÉ
Abs are vital to human immune responses and are composed of genetically variable H and L chains. These structures are initially expressed as BCRs. BCR diversity is shaped through somatic hypermutation and selection during immune responses. This evolutionary process produces B cell clones, cells that descend from a common ancestor but differ by mutations. Phylogenetic trees inferred from BCR sequences can reconstruct the history of mutations within a clone. Until recently, BCR sequencing technologies separated H and L chains, but advancements in single-cell sequencing now pair H and L chains from individual cells. However, it is unclear how these separate genes should be combined to infer B cell phylogenies. In this study, we investigated strategies for using paired H and L chain sequences to build phylogenetic trees. We found that incorporating L chains significantly improved tree accuracy and reproducibility across all methods tested. This improvement was greater than the difference between tree-building methods and persisted even when mixing bulk and single-cell sequencing data. However, we also found that many phylogenetic methods estimated significantly biased branch lengths when some L chains were missing, such as when mixing single-cell and bulk BCR data. This bias was eliminated using maximum likelihood methods with separate branch lengths for H and L chain gene partitions. Thus, we recommend using maximum likelihood methods with separate H and L chain partitions, especially when mixing data types. We implemented these methods in the R package Dowser: https://dowser.readthedocs.io.
Sujet(s)
Lymphocytes B , Phylogenèse , Récepteurs pour l'antigène des lymphocytes B , Humains , Récepteurs pour l'antigène des lymphocytes B/génétique , Récepteurs pour l'antigène des lymphocytes B/immunologie , Lymphocytes B/immunologie , Chaines lourdes des immunoglobulines/génétique , Chaines légères des immunoglobulines/génétique , Chaines légères des immunoglobulines/immunologie , Analyse sur cellule unique/méthodes , MutationRÉSUMÉ
Light chain amyloidosis (AL) is a systemic disease where fibrillar deposition of misfolded immunoglobulin light chains (LCs) severely affects organ function and results in poor prognosis for patients, especially when heart involvement is severe. Particularly relevant in this context is the cardiotoxicity exerted by still uncharacterized soluble LC species. Here, with the final goal of identifying alternative therapeutic strategies to tackle AL amyloidosis, we produced five llama-derived nanobodies (Nbs) specific against H3, a well-characterized amyloidogenic and cardiotoxic LC from an AL patient with severe cardiac involvement. We found that Nbs are specific and potent agents capable of abolishing H3 soluble toxicity in C. elegans in vivo model. Structural characterization of H3-Nb complexes revealed that the protective effect of Nbs is related to their ability to bind to the H3 VL domain and stabilise an unexpected partially open LC dimer in which the two VL domains no longer interact with each other. Thus, while identifying potent inhibitors of LC soluble toxicity, we also describe the first non-native structure of an amyloidogenic LC that may represent a crucial step in toxicity and aggregation mechanisms.
Sujet(s)
Amyloïde , Chaines légères des immunoglobulines , Amylose à chaine légère d'immunoglobuline , Anticorps à domaine unique , Animaux , Humains , Amyloïde/immunologie , Caenorhabditis elegans , Chaines légères des immunoglobulines/composition chimique , Chaines légères des immunoglobulines/immunologie , Chaines légères des immunoglobulines/usage thérapeutique , Myocytes cardiaques/métabolisme , Anticorps à domaine unique/composition chimique , Anticorps à domaine unique/immunologie , Anticorps à domaine unique/usage thérapeutique , Amylose à chaine légère d'immunoglobuline/immunologie , Amylose à chaine légère d'immunoglobuline/thérapieRÉSUMÉ
Despite the vast diversity of the antibody repertoire, infected individuals often mount antibody responses to precisely the same epitopes within antigens. The immunological mechanisms underpinning this phenomenon remain unknown. By mapping 376 immunodominant "public epitopes" at high resolution and characterizing several of their cognate antibodies, we concluded that germline-encoded sequences in antibodies drive recurrent recognition. Systematic analysis of antibody-antigen structures uncovered 18 human and 21 partially overlapping mouse germline-encoded amino acid-binding (GRAB) motifs within heavy and light V gene segments that in case studies proved critical for public epitope recognition. GRAB motifs represent a fundamental component of the immune system's architecture that promotes recognition of pathogens and leads to species-specific public antibody responses that can exert selective pressure on pathogens.
Sujet(s)
Motifs d'acides aminés , Production d'anticorps , Interactions hôte-pathogène , Épitopes immunodominants , Chaines lourdes des immunoglobulines , Chaines légères des immunoglobulines , Animaux , Humains , Souris , Cellules germinales , Épitopes immunodominants/composition chimique , Épitopes immunodominants/génétique , Chaines lourdes des immunoglobulines/génétique , Chaines lourdes des immunoglobulines/immunologie , Chaines légères des immunoglobulines/génétique , Chaines légères des immunoglobulines/immunologie , Cartographie épitopique , Interactions hôte-pathogène/génétique , Interactions hôte-pathogène/immunologieRÉSUMÉ
Broadly neutralizing antibodies (bnAbs) can protect against HIV infection but have not been induced by human vaccination. A key barrier to bnAb induction is vaccine priming of rare bnAb-precursor B cells. In a randomized, double-blind, placebo-controlled phase 1 clinical trial, the HIV vaccine-priming candidate eOD-GT8 60mer adjuvanted with AS01B had a favorable safety profile and induced VRC01-class bnAb precursors in 97% of vaccine recipients with median frequencies reaching 0.1% among immunoglobulin G B cells in blood. bnAb precursors shared properties with bnAbs and gained somatic hypermutation and affinity with the boost. The results establish clinical proof of concept for germline-targeting vaccine priming, support development of boosting regimens to induce bnAbs, and encourage application of the germline-targeting strategy to other targets in HIV and other pathogens.
Sujet(s)
Vaccins contre le SIDA , Anticorps neutralisants à large spectre , Cellules germinales , Anticorps anti-VIH , Infections à VIH , Chaines lourdes des immunoglobulines , Chaines légères des immunoglobulines , Humains , Adjuvants immunologiques , Vaccins contre le SIDA/immunologie , Anticorps neutralisants à large spectre/génétique , Anticorps neutralisants à large spectre/immunologie , Infections à VIH/prévention et contrôle , Vaccination , Anticorps anti-VIH/génétique , Anticorps anti-VIH/immunologie , Cellules germinales/immunologie , Lymphocytes B/immunologie , Mutation , Chaines légères des immunoglobulines/génétique , Chaines légères des immunoglobulines/immunologie , Chaines lourdes des immunoglobulines/génétique , Chaines lourdes des immunoglobulines/immunologie , Mâle , Femelle , AdulteRÉSUMÉ
The vertebrate adaptive immune system modifies the genome of individual B cells to encode antibodies that bind particular antigens1. In most mammals, antibodies are composed of heavy and light chains that are generated sequentially by recombination of V, D (for heavy chains), J and C gene segments. Each chain contains three complementarity-determining regions (CDR1-CDR3), which contribute to antigen specificity. Certain heavy and light chains are preferred for particular antigens2-22. Here we consider pairs of B cells that share the same heavy chain V gene and CDRH3 amino acid sequence and were isolated from different donors, also known as public clonotypes23,24. We show that for naive antibodies (those not yet adapted to antigens), the probability that they use the same light chain V gene is around 10%, whereas for memory (functional) antibodies, it is around 80%, even if only one cell per clonotype is used. This property of functional antibodies is a phenomenon that we call light chain coherence. We also observe this phenomenon when similar heavy chains recur within a donor. Thus, although naive antibodies seem to recur by chance, the recurrence of functional antibodies reveals surprising constraint and determinism in the processes of V(D)J recombination and immune selection. For most functional antibodies, the heavy chain determines the light chain.
Sujet(s)
Anticorps , Sélection clonale médiée par un antigène , Chaines lourdes des immunoglobulines , Chaines légères des immunoglobulines , Animaux , Séquence d'acides aminés , Anticorps/composition chimique , Anticorps/génétique , Anticorps/immunologie , Antigènes/composition chimique , Antigènes/immunologie , Lymphocytes B/cytologie , Lymphocytes B/immunologie , Lymphocytes B/métabolisme , Régions déterminant la complémentarité/composition chimique , Régions déterminant la complémentarité/immunologie , Chaines lourdes des immunoglobulines/composition chimique , Chaines lourdes des immunoglobulines/génétique , Chaines lourdes des immunoglobulines/immunologie , Mammifères , Chaines légères des immunoglobulines/composition chimique , Chaines légères des immunoglobulines/génétique , Chaines légères des immunoglobulines/immunologie , Mémoire immunologique , Recombinaison V(D)J , Sélection clonale médiée par un antigène/génétique , Sélection clonale médiée par un antigène/immunologieRÉSUMÉ
The antibody repertoires of individuals and groups have been used to explore disease states, understand vaccine responses, and drive therapeutic development. The arrival of B-cell receptor repertoire sequencing has enabled researchers to get a snapshot of these antibody repertoires, and as more data are generated, increasingly in-depth studies are possible. However, most publicly available data only exist as raw FASTQ files, making the data hard to access, process, and compare. The Observed Antibody Space (OAS) database was created in 2018 to offer clean, annotated, and translated repertoire data. In this paper, we describe an update to OAS that has been driven by the increasing volume of data and the appearance of paired (VH/VL) sequence data. OAS is now accessible via a new web server, with standardized search parameters and a new sequence-based search option. The new database provides both nucleotides and amino acids for every sequence, with additional sequence annotations to make the data Minimal Information about Adaptive Immune Receptor Repertoire compliant, and comments on potential problems with the sequence. OAS now contains 25 new studies, including severe acute respiratory syndrome coronavirus 2 data and paired sequencing data. The new database is accessible at http://opig.stats.ox.ac.uk/webapps/oas/, and all data are freely available for download.
Sujet(s)
Anticorps/composition chimique , Bases de données de protéines , Séquence d'acides aminés , Animaux , Anticorps/immunologie , COVID-19/immunologie , Humains , Chaines lourdes des immunoglobulines/composition chimique , Chaines lourdes des immunoglobulines/immunologie , Chaines légères des immunoglobulines/composition chimique , Chaines légères des immunoglobulines/immunologie , Région variable d'immunoglobuline/composition chimique , Région variable d'immunoglobuline/immunologie , SARS-CoV-2/immunologieRÉSUMÉ
Plasma cells and their secreted antibodies play a central role in the long-term protection against chronic viral infection. However, due to experimental limitations, a comprehensive description of linked genotypic, phenotypic, and antibody repertoire features of plasma cells (gene expression, clonal frequency, virus specificity, and affinity) has been challenging to obtain. To address this, we performed single-cell transcriptome and antibody repertoire sequencing of the murine BM plasma cell population following chronic lymphocytic choriomeningitis virus infection. Our single-cell sequencing approach recovered full-length and paired heavy- and light-chain sequence information for thousands of plasma cells and enabled us to perform recombinant antibody expression and specificity screening. Antibody repertoire analysis revealed that, relative to protein immunization, chronic infection led to increased levels of clonal expansion, class-switching, and somatic variants. Furthermore, antibodies from the highly expanded and class-switched (IgG) plasma cells were found to be specific for multiple viral antigens and a subset of clones exhibited cross-reactivity to nonviral and autoantigens. Integrating single-cell transcriptome data with antibody specificity suggested that plasma cell transcriptional phenotype was correlated to viral antigen specificity. Our findings demonstrate that chronic viral infection can induce and sustain plasma cell clonal expansion, combined with significant somatic hypermutation, and can generate cross-reactive antibodies.
Sujet(s)
Anticorps antiviraux , Sélection clonale médiée par un antigène , Chaines lourdes des immunoglobulines , Chaines légères des immunoglobulines , Chorioméningite lymphocytaire , Virus de la chorioméningite lymphocytaire/immunologie , Plasmocytes/immunologie , Analyse sur cellule unique , Animaux , Anticorps antiviraux/génétique , Anticorps antiviraux/immunologie , Maladie chronique , Femelle , Chaines lourdes des immunoglobulines/génétique , Chaines lourdes des immunoglobulines/immunologie , Chaines légères des immunoglobulines/génétique , Chaines légères des immunoglobulines/immunologie , Chorioméningite lymphocytaire/génétique , Chorioméningite lymphocytaire/immunologie , SourisRÉSUMÉ
The current pneumococcal capsular polysaccharide (PPS) conjugate vaccine (PCV13) is less effective against Streptococcus pneumoniae serotype 3 (ST3), which remains a major cause of pneumococcal disease and mortality. Therefore, dissecting structure-function relationships of human ST3 pneumococcal capsular polysaccharide (PPS3) antibodies may reveal characteristics of protective antibodies. Using flow cytometry, we isolated PPS3-binding memory B cells from pneumococcal vaccine recipients and generated seven PPS3-specific human monoclonal antibodies (humAbs). Five humAbs displayed ST3 opsonophagocytic activity, four induced ST3 agglutination in vitro, and four mediated both activities. Two humAbs, namely, C10 and C27, that used the same variable heavy (VH) and light (VL) chain domains (VH3-9*01/VL2-14*03) both altered ST3 gene expression in vitro; however, C10 had fewer VL somatic mutations, higher PPS3 affinity, and promoted in vitro ST3 opsonophagocytic and agglutinating activity, whereas C27 did not. In C57BL/6 mice, both humAbs reduced nasopharyngeal colonization with ST3 A66 and a clinical strain, B2, and prolonged survival following lethal A66 intraperitoneal infection, but only C10 protected against lethal intranasal infection with the clinical strain. After performing VL swaps, C10VH/C27VL exhibited reduced ST3 binding and agglutination, but C27VH/C10VL binding was unchanged. However, both humAbs lost the ability to reduce colonization in vivo when their light chains were replaced. Our findings associate the ability of PPS3-specific humAbs to reduce colonization with ST3 agglutination and opsonophagocytic activity, and reveal an unexpected role for the VL in their functional activity in vitro and in vivo. These findings also provide insights that may inform antibody-based therapy and identification of surrogates of vaccine efficacy against ST3. IMPORTANCE Despite the global success of vaccination with pneumococcal conjugate vaccines, serotype 3 (ST3) pneumococcus remains a leading cause of morbidity and mortality. In comparison to other vaccine-included serotypes, the ST3 pneumococcal capsular polysaccharide (PPS3) induces a weaker opsonophagocytic response, which is considered a correlate of vaccine efficacy. Previous studies of mouse PPS3 monoclonal antibodies identified ST3 agglutination as a correlate of reduced ST3 nasopharyngeal colonization in mice; however, neither the agglutinating ability of human vaccine-elicited PPS3 antibodies nor their ability to prevent experimental murine nasopharyngeal colonization has been studied. We generated and analyzed the functional and in vivo efficacy of human vaccine-elicited PPS3 monoclonal antibodies and found that ST3 agglutination associated with antibody affinity, protection in vivo, and limited somatic mutations in the light chain variable region. These findings provide new insights that may inform the development of antibody-based therapies and next-generation vaccines for ST3.
Sujet(s)
Anticorps antibactériens/immunologie , Anticorps monoclonaux/immunologie , Capsules bactériennes/immunologie , Polyosides bactériens/immunologie , Streptococcus pneumoniae/immunologie , Animaux , Affinité des anticorps/immunologie , Lignée cellulaire , Femelle , Cellules HEK293 , Humains , Fragments Fab d'immunoglobuline/génétique , Fragments Fab d'immunoglobuline/immunologie , Chaines lourdes des immunoglobulines/génétique , Chaines lourdes des immunoglobulines/immunologie , Chaines légères des immunoglobulines/génétique , Chaines légères des immunoglobulines/immunologie , Souris , Souris de lignée C57BL , Partie nasale du pharynx/immunologie , Partie nasale du pharynx/microbiologie , Opsonisation/immunologie , Vaccins antipneumococciques/immunologie , Pneumonie à pneumocoques/immunologie , Pneumonie à pneumocoques/mortalité , Sérogroupe , Anticorps à chaîne unique/immunologie , Streptococcus pneumoniae/classification ,RÉSUMÉ
Understanding mechanisms of protective antibody recognition can inform vaccine and therapeutic strategies against SARS-CoV-2. We report a monoclonal antibody, 910-30, targeting the SARS-CoV-2 receptor-binding site for ACE2 as a member of a public antibody response encoded by IGHV3-53/IGHV3-66 genes. Sequence and structural analyses of 910-30 and related antibodies explore how class recognition features correlate with SARS-CoV-2 neutralization. Cryo-EM structures of 910-30 bound to the SARS-CoV-2 spike trimer reveal binding interactions and its ability to disassemble spike. Despite heavy-chain sequence similarity, biophysical analyses of IGHV3-53/3-66-encoded antibodies highlight the importance of native heavy:light pairings for ACE2-binding competition and SARS-CoV-2 neutralization. We develop paired heavy:light class sequence signatures and determine antibody precursor prevalence to be â¼1 in 44,000 human B cells, consistent with public antibody identification in several convalescent COVID-19 patients. These class signatures reveal genetic, structural, and functional immune features that are helpful in accelerating antibody-based medical interventions for SARS-CoV-2.
Sujet(s)
Angiotensin-converting enzyme 2/immunologie , Anticorps monoclonaux/composition chimique , Anticorps monoclonaux/immunologie , COVID-19/immunologie , COVID-19/virologie , SARS-CoV-2/immunologie , Glycoprotéine de spicule des coronavirus/immunologie , Sujet âgé , Angiotensin-converting enzyme 2/composition chimique , Animaux , Anticorps monoclonaux/génétique , Anticorps monoclonaux/ultrastructure , Anticorps neutralisants/immunologie , Anticorps antiviraux/immunologie , Production d'anticorps , Lymphocytes B/immunologie , Sites de fixation , Chlorocebus aethiops , Cryomicroscopie électronique , Cellules HEK293 , Humains , Chaines lourdes des immunoglobulines/composition chimique , Chaines lourdes des immunoglobulines/génétique , Chaines lourdes des immunoglobulines/immunologie , Chaines lourdes des immunoglobulines/ultrastructure , Chaines légères des immunoglobulines/composition chimique , Chaines légères des immunoglobulines/génétique , Chaines légères des immunoglobulines/immunologie , Chaines légères des immunoglobulines/ultrastructure , Mâle , Liaison aux protéines , Motifs et domaines d'intéraction protéique , SARS-CoV-2/composition chimique , Glycoprotéine de spicule des coronavirus/composition chimique , Cellules VeroRÉSUMÉ
In humans, orthohantaviruses can cause hemorrhagic fever with renal syndrome (HFRS) or hantavirus pulmonary syndrome (HPS). An earlier study reported that acute Andes virus HPS caused a massive and transient elevation in the number of circulating plasmablasts with specificity towards both viral and host antigens suggestive of polyclonal B cell activation. Immunoglobulins (Igs), produced by different B cell populations, comprise heavy and light chains; however, a certain amount of free light chains (FLCs) is constantly present in serum. Upregulation of FLCs, especially clonal species, associates with renal pathogenesis by fibril or deposit formations affecting the glomeruli, induction of epithelial cell disorders, or cast formation in the tubular network. We report that acute orthohantavirus infection increases the level of Ig FLCs in serum of both HFRS and HPS patients, and that the increase correlates with the severity of acute kidney injury in HFRS. The fact that the kappa to lambda FLC ratio in the sera of HFRS and HPS patients remained within the normal range suggests polyclonal B cell activation rather than proliferation of a single B cell clone. HFRS patients demonstrated increased urinary excretion of FLCs, and we found plasma cell infiltration in archival patient kidney biopsies that we speculate to contribute to the observed FLC excreta. Analysis of hospitalized HFRS patients' peripheral blood mononuclear cells showed elevated plasmablast levels, a fraction of which stained positive for Puumala virus antigen. Furthermore, B cells isolated from healthy donors were susceptible to Puumala virus in vitro, and the virus infection induced increased production of Igs and FLCs. The findings propose that hantaviruses directly activate B cells, and that the ensuing intense production of polyclonal Igs and FLCs may contribute to acute hantavirus infection-associated pathological findings.
Sujet(s)
Atteinte rénale aigüe/anatomopathologie , Lymphocytes B/immunologie , Infections à hantavirus/immunologie , Chaines légères des immunoglobulines/sang , Activation des lymphocytes/immunologie , Orthohantavirus/immunologie , Atteinte rénale aigüe/sang , Atteinte rénale aigüe/étiologie , Infections à hantavirus/sang , Infections à hantavirus/virologie , Humains , Chaines légères des immunoglobulines/immunologieRÉSUMÉ
Distinguishing between severe and nonsevere COVID-19 to ensure adequate healthcare quality and efficiency is a challenge for the healthcare system. The aim of this study was to assess the usefulness of CBC parameters together with analysis of FLC serum concentration in risk stratification of COVID-19. MATERIALS AND METHODS: CBC was analyzed in 735 COVID ICU, COVID non-ICU, and non-COVID ICU cases. FLC concentration was analyzed in 133 of them. RESULTS: COVID ICU had neutrophils and lymphocytes with the greatest size, granularity, and nucleic acid content. Significant differences in concentrations of κ and λ FLCs were shown between COVID ICU and COVID non-ICU. However, no difference was found in the κ/λ ratio between these groups, and the ratio stayed within the reference value, which indicates the presence of polyclonal FLCs. FLC κ measurement has significant power to distinguish between severe COVID-19 and nonsevere COVID-19 (AUC = 0.7669), with a sensitivity of 86.67% and specificity of 93.33%. The κ coefficients' odds ratio of 3.0401 was estimated. CONCLUSION: It can be concluded that the results obtained from the measure of free light immunoglobulin concentration in serum are useful in distinguishing between severe and nonsevere COVID-19.
Sujet(s)
COVID-19/immunologie , Chaines légères des immunoglobulines/sang , SARS-CoV-2/immunologie , Sujet âgé , Sujet âgé de 80 ans ou plus , Protéine C-réactive/immunologie , COVID-19/sang , COVID-19/diagnostic , Dépistage sérologique de la COVID-19 , Femelle , Ferritines/immunologie , Humains , Chaines légères des immunoglobulines/immunologie , Unités de soins intensifs , Interleukine-6/immunologie , Mâle , Adulte d'âge moyen , Études rétrospectives , Sensibilité et spécificité , Indice de gravité de la maladieRÉSUMÉ
We studied the contribution of the light chain to functions of human monoclonal antibodies (mAbs) by measuring the relationships between the rate of mutations and cross-reactivity, binding affinity and neutralization activity. We analyzed 12 mAbs of two clonal families specific to the V2 region of HIV-1 derived from two chronically HIV-1 infected individuals. The clonal mAbs exhibited a range of reactivities, and the clones with superior properties were associated with the rate of mutations and the presence of particular mutated residues in the light chains, but not in the heavy chains. Our observations suggest that for some antibodies, the light chains play a vital role in antibody evolution toward more efficient ones and also suggest the importance of optimal residues rather than the rate of mutations in the variable fragment of the antibody.
Sujet(s)
Anticorps monoclonaux , Anticorps anti-VIH , Infections à VIH , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/immunologie , Chaines légères des immunoglobulines , Région variable d'immunoglobuline , Adulte , Anticorps monoclonaux/génétique , Anticorps monoclonaux/immunologie , Femelle , Anticorps anti-VIH/génétique , Anticorps anti-VIH/immunologie , Infections à VIH/génétique , Infections à VIH/immunologie , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/génétique , Humains , Chaines légères des immunoglobulines/génétique , Chaines légères des immunoglobulines/immunologie , Région variable d'immunoglobuline/génétique , Région variable d'immunoglobuline/immunologie , MâleRÉSUMÉ
Lenalidomide and dexamethasone (RD) is a standard treatment in relapsed/refractory immunoglobulin light chain (AL) amyloidosis (RRAL). We retrospectively investigated toxicity, efficacy and prognostic markers in 260 patients with RRAL. Patients received a median of two prior treatment lines (68% had been bortezomib-refractory; 33% had received high-dose melphalan). The median treatment duration was four cycles. The 3-month haematological response rate was 31% [very good haematological response (VGHR) in 18%]. The median follow-up was 56·5 months and the median overall survival (OS) and haematological event-free survival (haemEFS) were 32 and 9 months. The 2-year dialysis rate was 15%. VGHR resulted in better OS (62 vs. 26 months, P < 0·001). Cardiac progression predicted worse survival (22 vs. 40 months, P = 0·027), although N-terminal prohormone of brain natriuretic peptide (NT-proBNP) increase was frequently observed. Multivariable analysis identified these prognostic factors: NT-proBNP for OS [hazard ratio (HR) 1·71; P < 0·001]; gain 1q21 for haemEFS (HR 1·68, P = 0·014), with a trend for OS (HR 1·47, P = 0·084); difference between involved and uninvolved free light chains (dFLC) and light chain isotype for OS (HR 2·22, P < 0·001; HR 1·62, P = 0·016) and haemEFS (HR 1·88, P < 0·001; HR 1·59, P = 0·008). Estimated glomerular filtration rate (HR 0·71, P = 0·004) and 24-h proteinuria (HR 1·10, P = 0·004) were prognostic for renal survival. In conclusion, clonal and organ biomarkers at baseline identify patients with favourable outcome, while VGHR and cardiac progression define prognosis during RD treatment.
Sujet(s)
Dexaméthasone/usage thérapeutique , Chaines légères des immunoglobulines/métabolisme , Amylose à chaine légère d'immunoglobuline/diagnostic , Amylose à chaine légère d'immunoglobuline/traitement médicamenteux , Lénalidomide/usage thérapeutique , Adulte , Sujet âgé , Antinéoplasiques hormonaux/administration et posologie , Antinéoplasiques hormonaux/usage thérapeutique , Antinéoplasiques hormonaux/toxicité , Marqueurs biologiques/métabolisme , Études de cohortes , Dexaméthasone/administration et posologie , Dexaméthasone/toxicité , Association de médicaments/méthodes , Femelle , Études de suivi , Humains , Chaines légères des immunoglobulines/immunologie , Amylose à chaine légère d'immunoglobuline/immunologie , Amylose à chaine légère d'immunoglobuline/mortalité , Facteurs immunologiques/administration et posologie , Facteurs immunologiques/usage thérapeutique , Facteurs immunologiques/toxicité , Lénalidomide/administration et posologie , Lénalidomide/toxicité , Mâle , Adulte d'âge moyen , Peptide natriurétique cérébral/métabolisme , Fragments peptidiques/métabolisme , Pronostic , Survie sans progression , Récidive , Études rétrospectivesRÉSUMÉ
OBJECTIVES: Follicular hyperplasias (FHs) with light chain-restricted (LCR) plasmacytoid/plasma cells (PCs) within germinal centers (GCs) based on immunohistochemistry (IHC)/in situ hybridization (ISH) can potentially lead to diagnostic error. This study aims to better characterize such cases, including their clinical implications. METHODS: LC expression by IHC/ISH was quantitatively assessed in GCs of 17 FHs with LCRGCs. BCL2, CD10, BCL6, BCL2, immunoglobulin (Ig) heavy chains, IgG4, and Epstein-Barr encoding region stains were performed. In total, 8 cases had polymerase chain reaction (PCR)-based clonality studies. RESULTS: All cases showed FH, including 4 with progressively transformed GCs (PTGCs); 0.8% to 52% (median, 21%) of the GCs were LCR; 13 of 17 had both κ- and λ-LCRGCs, and 4 of 17 had only κ-LCRGCs; 7 of 16 had prominent intrafollicular IgG4-positive cells. One case demonstrated BCL2-positive cells in focal LCRGCs but lacked BCL2 rearrangement. B-cell monoclonality was demonstrated in 3 of 8 cases (only after microdissection). Seven patients had autoimmune disorders, and 1 had had a transplant. Three patients had a history of lymphoma, 1 developed lymphoma, and 1 developed lymphomatoid granulomatosis subsequently. CONCLUSIONS: FHs with LCRGC by IHC/ISH are typically not associated with the development of lymphoma, even though they can express BCL2 and show monoclonality by PCR. They may be associated with increased intrafollicular IgG4-positive cells, PTGC, and autoimmunity.
Sujet(s)
Centre germinatif/immunologie , Centre germinatif/anatomopathologie , Chaines légères des immunoglobulines/immunologie , Plasmocytes/immunologie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Diagnostic différentiel , Femelle , Humains , Hyperplasie/immunologie , Hyperplasie/anatomopathologie , Lymphomes/diagnostic , Lymphomes/immunologie , Lymphomes/anatomopathologie , Syndromes lymphoprolifératifs/diagnostic , Syndromes lymphoprolifératifs/immunologie , Syndromes lymphoprolifératifs/anatomopathologie , Mâle , Adulte d'âge moyen , Plasmocytes/anatomopathologie , Études rétrospectivesRÉSUMÉ
Assembly of IgG-like asymmetric bispecific antibodies (bsAbs) requires heavy chain heterodimerization and cognate heavy-light chain pairings. Multiple strategies have been developed to solve these chain association issues. While these strategies greatly promote correct chain pairing, they normally cannot prevent low amount of chain mispaired byproducts from being generated. Besides, byproducts can also be generated as a result of discordant chain expression. The existence of various byproducts poses considerable challenges to downstream processing during the production of recombinant IgG-like bsAbs. In many cases, yield is greatly compromised for purity improvement. This mini review introduces eight IgG-like bsAb platforms, which share a common feature: they all contain built-in purification-facilitating elements in addition to chain pairing control designs. These platforms, by simultaneously providing solutions to the two issues associated with bsAb production (i.e., correct chain pairing and efficient purification), improve both efficiency and robustness of bsAb production.